The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
Open accessAbstract
Background: Interleukin‐6 ( IL ‐6) is an inflammatory cytokine implicated in plaque instability in acute coronary syndrome ( ACS ). We aimed to evaluate the prognostic implications of IL ‐6 post‐ ACS . Methods and Results: IL ‐6 concentration was assessed at baseline in 4939 subjects in SOLID ‐ TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52), a randomized trial of darapladib in patients ≤30 days from ACS . Patients were followed for a median of 2.5 years for major adverse cardiovascular events; cardiovascular death, myocardial infarction, or stroke) and cardiovascular death or heart failure hospitalization. Primary analyses were adjusted first for baseline characteristics, days from index ACS , ACS type, and randomized treatment arm. For every SD increase in IL ‐6, there was a 10% higher risk of major adverse cardiovascular events (adjusted hazard ratio [adj HR ] 1.10, 95% confidence interval [ CI ] 1.01‐1.19) and a 22% higher risk of cardiovascular death or heart failure (adj HR 1.22, 95% CI 1.11‐1.34). Patients in the highest IL ‐6 quartile had a higher risk of major adverse cardiovascular events (adj HR Q4:Q1 1.57, 95% CI 1.22‐2.03) and cardiovascular death or heart failure (adj HR 2.29, 95% CI 1.6‐3.29). After further adjustment for biomarkers (high‐sensitivity C‐reactive protein, lipoprotein‐associated phospholipase A 2 activity, high‐sensitivity troponin I, and B‐type natriuretic peptide), IL ‐6 remained significantly associated with the risk of major adverse cardiovascular events (adj HR Q4:Q1 1.43, 95% CI 1.09‐1.88) and cardiovascular death or heart failure (adj HR 1.79, 95% CI 1.22‐2.63). Conclusions: In patients after ACS , IL ‐6 concentration is associated with adverse cardiovascular outcomes independent of established risk predictors and biomarkers. These findings lend support to the concept of IL ‐6 as a potential therapeutic target in patients with unstable ischemic heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Progress and challenges in translating the biology of atherosclerosis
Libby, P., Ridker, P. M., & Hansson, G. K. (2011) · Nature · doi:10.1038/nature10146 · Cited by 4,010
Ridker, P. M., Rifai, N., Stampfer, M. J., & Hennekens, C. H. (2000) · Circulation · doi:10.1161/01.cir.101.15.1767 · Cited by 2,429
(2012) · The Lancet · doi:10.1016/s0140-6736(11)61931-4 · Cited by 823
Everett, B. M., Pradhan, A. D., Solomon, D. H., Paynter, N., MacFadyen, J., Zaharris, E., Gupta, M., Clearfield, M., Libby, P., Hasan, A. A. K., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.03.018 · Cited by 368
Kothari, P., Pestana, R., Mesraoua, R., Elchaki, R., Khan, K. M. F., Dannenberg, A. J., & Falcone, D. J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301906 · Cited by 137
Cited by
Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Heart Failure After Myocardial Infarction: Incidence and Predictors
Jenča, D., Melenovský, V., Stehlik, J., Staněk, V., Kettner, J., Kautzner, J., Adámková, V., & Wohlfahrt, P. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13144 · Cited by 605
Ridker, P. M., Libby, P., MacFadyen, J. G., Thuren, T., Ballantyne, C., Fonseca, F., Koenig, W., Shimokawa, H., Everett, B. M., & Glynn, R. J. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy310 · Cited by 544
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Matter, M. A., Paneni, F., Libby, P., Frantz, S., Stähli, B. E., Templin, C., Mengozzi, A., Wang, Y.-J., Kündig, T. M., Räber, L., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad486 · Cited by 357
Role of cytokines and inflammation in heart function during health and disease
Bartekova, M., Radosinska, J., Jelemensky, M., & Dhalla, N. S. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9716-x · Cited by 293
Metadata
- Authors
- Fanola, C. L., Morrow, D. A., Cannon, C. P., Jarolim, P., Lukas, M. A., Bode, C., Hochman, J. S., Goodrich, E. L., Braunwald, E., & O'Donoghue, M. L.
- Venue
- Journal of the American Heart Association
- Published
- 2017-10-11
- Volume
- 6
- Issue
- 10
- ISSN
- 2047-9980 (ISSN-L)
- OpenAlex
- W2767035638
- Cited by
- 162
- References
- 7
- FWCI
- 8.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial. https://app.cochat.ai/papers/10.1161/jaha.117.005637
- The paper
- Fanola, C. L., Morrow, D. A., Cannon, C. P., Jarolim, P., Lukas, M. A., Bode, C., Hochman, J. S., Goodrich, E. L., Braunwald, E., & O'Donoghue, M. L. (2017). Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.117.005637
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.